Business
Rigel to Present Two Posters Highlighting Fostamatinib at the 24 Congress of the European Hematology Association (EHA)
SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019. Data presented will overview long-term safety and efficacy of fostamatinib from the FIT Phase 3 extension study (FIT3) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Additionally, Rigel will highlight data from its open-label extension period of the SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA). The abstracts are available on the EHA website at www.ehaweb.org/congress.\nFostamatinib is an oral drug designed to inhibit spleen tyrosine kinase (SYK), a key signaling component of the body's immune process that is believed to lead to platelet destruction in ITP and red blood cell destruction in AIHA. Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib), which is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. Fostamatinib1 is currently being investigated in a Phase 3 registrational trial in AIHA, a rare, serious blood disorder in which the immune system produces antibodies that result in the destruction of the body's own healthy red blood cells and for which there are currently no approved therapies.\nPoster PresentationsAbstract #PF703Title: Long-term Fostamatinib Treatment of Adults with Immune Thrombocytopenia (ITP) During the Phase 3 Clinical Trial ProgramSession Title: Platelets disordersDate: Friday, June 14Presentation Time: 5:30 - 7:00 PM CESTLocation: RAI Amsterdam – Amsterdam, Netherlands\nAbstract # PF427Title: Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Open-Label Extension Period of the SOAR Phase 2 StudySession Title: Enzymopathies, membranopathies and other anemiasDate: Friday, June 14Presentation Time: 5:30 - 7:00 PM CESTLocation: RAI Amsterdam – Amsterdam, Netherlands\nAbout ITP...